INVA
Price:
$17.72
Market Cap:
$1.11B
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group...[Read more]
Industry
Biotechnology
IPO Date
2004-10-05
Stock Exchange
NASDAQ
Ticker
INVA
According to Innoviva, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.10B. This represents a change of -11.25% compared to the average of 1.24B of the last 4 quarters.
The mean historical Enterprise Value of Innoviva, Inc. over the last ten years is 1.70B. The current 1.10B Enterprise Value has changed 6.41% with respect to the historical average. Over the past ten years (40 quarters), INVA's Enterprise Value was at its highest in in the June 2015 quarter at 2.63B. The Enterprise Value was at its lowest in in the September 2020 quarter at 963.35M.
Average
1.70B
Median
1.69B
Minimum
1.27B
Maximum
2.15B
Discovering the peaks and valleys of Innoviva, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 15.37%
Maximum Annual Enterprise Value = 2.15B
Minimum Annual Increase = -26.39%
Minimum Annual Enterprise Value = 1.27B
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.31B | 2.80% |
2022 | 1.27B | -21.08% |
2021 | 1.61B | 15.37% |
2020 | 1.39B | -8.94% |
2019 | 1.53B | -26.39% |
2018 | 2.08B | 1.79% |
2017 | 2.04B | 14.93% |
2016 | 1.78B | -1.50% |
2015 | 1.81B | -15.86% |
2014 | 2.15B | -25.48% |
The current Enterprise Value of Innoviva, Inc. (INVA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
1.39B
5-year avg
1.42B
10-year avg
1.70B
Innoviva, Inc.’s Enterprise Value is greater than eFFECTOR Therapeutics, Inc. (4.74M), greater than Protalix BioTherapeutics, Inc. (109.34M), greater than PDS Biotechnology Corporation (36.27M), greater than aTyr Pharma, Inc. (138.44M), greater than Elevation Oncology, Inc. (18.15M), greater than Day One Biopharmaceuticals, Inc. (848.49M), less than Mirati Therapeutics, Inc. (3.91B), greater than Amylyx Pharmaceuticals, Inc. (206.98M), greater than Terns Pharmaceuticals, Inc. (214.26M), less than Apellis Pharmaceuticals, Inc. (4.12B), greater than X4 Pharmaceuticals, Inc. (95.74M), greater than Inozyme Pharma, Inc. (205.94M), greater than HOOKIPA Pharma Inc. (-38580462.00), greater than Acumen Pharmaceuticals, Inc. (103.15M), less than Amicus Therapeutics, Inc. (3.11B), less than Incyte Corporation (12.19B), less than Denali Therapeutics Inc. (2.93B), less than argenx SE (36.50B), less than Harmony Biosciences Holdings, Inc. (1.73B),
Company | Enterprise Value | Market cap |
---|---|---|
4.74M | $941.00 | |
109.34M | $131.07M | |
36.27M | $61.35M | |
138.44M | $131.12M | |
18.15M | $35.34M | |
848.49M | $1.27B | |
3.91B | $4.12B | |
206.98M | $276.25M | |
214.26M | $483.09M | |
4.12B | $4.04B | |
95.74M | $114.95M | |
205.94M | $183.73M | |
-38580462.00 | $18.34M | |
103.15M | $106.34M | |
3.11B | $2.89B | |
12.19B | $13.46B | |
2.93B | $2.97B | |
36.50B | $37.90B | |
1.73B | $1.94B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innoviva, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Innoviva, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Innoviva, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Innoviva, Inc. (INVA)?
What is the 3-year average Enterprise Value for Innoviva, Inc. (INVA)?
What is the 5-year average Enterprise Value for Innoviva, Inc. (INVA)?
How does the current Enterprise Value for Innoviva, Inc. (INVA) compare to its historical average?